Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0015674 (
chronic fatigue syndrome
)
2,978
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Background:
Concise methodological directions for administration of serial cardiopulmonary exercise testing (CPET) are needed for testing of patients with
Myalgic Encephalomyelitis
/
Chronic Fatigue Syndrome
(ME/
CFS
). Maximal CPET is used to evaluate the coordinated metabolic, muscular, respiratory and cardiac contributions to energy production in patients with ME/
CFS
. In this patient population, CPET also elicits a robust post-exertional symptom flare (termed, post-exertional malaise); a cardinal symptom of the disease. CPET measures are highly reliable and reproducible in both healthy and diseased populations. However, evidence to date indicates that ME/
CFS
patients are uniquely unable to reproduce CPET measures during a second test, despite giving maximal effort during both tests, due to the effects of
PEM
on energy production.
Methodology:
To document and assess functional impairment due to the effects of post-exertional malaise in ME/
CFS
, a 2-day CPET procedure (2-day CPET) has been used to first measure baseline functional capacity (CPET1) and provoke post-exertional malaise, then assess changes in CPET variables 24 h later with a second CPET to assess the effects of post-exertional malaise on functional capacity. The second CPET measures changes in energy production and physiological function, objectively documenting the effects of post-exertional malaise. Use of CPET as a standardized stressor to induce post-exertional malaise and quantify impairment associated with post-exertional malaise has been employed to examine ME/
CFS
pathology in several studies. This article discusses the results of those studies, as well as the standardized techniques and procedures for use of the 2-day CPET in ME/
CFS
patients, and potentially other fatiguing illnesses.
Conclusions:
Basic concepts of CPET are summarized, and special considerations for performing CPET on ME/
CFS
patients are detailed to ensure a valid outcome. The 2-day CPET methodology is outlined, and the utility of the procedure is discussed for assessment of functional capacity and exertion intolerance in ME/
CFS
.
...
PMID:Cardiopulmonary Exercise Test Methodology for Assessing Exertion Intolerance in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. 3023 78
Systemic Exertion Intolerance Disease (SEID) or
myalgic encephalomyelitis
(ME) or
chronic fatigue syndrome
(
CFS
) has an unknown aetiology, with no known treatment and a prevalence of approximately 22 million individuals (2%) in Western countries. Although strongly suspected, the role of lactate in pathology is unknown, nor has the nature of the two most central symptoms of the condition - post exertional malaise and fatigue. The proposed mechanism of action of pyruvate dehydrogenase complex (PDC) plays a central role in maintaining energy production with cofactors alpha-lipoic acid (LA) and its counterpart dihydrolipoic acid (DHLA), its regeneration suggested as the new rate limiting factor. Decreased DHLA regeneration due to impairment of the E
3
subunit or crossover of the swinging arms of the E
2
subunit of PDC have been suggested as a cause of ME/
CFS
/SEID resulting in instantaneous fluctuations in lactate levels and instantaneous offset of the DHLA/LA ratio and defining the condition as an LA deficiency with chronic instantaneous hyperlactataemia with explicit stratification of symptoms. While instantaneous hyperlactataemia has been suggested to account for the
PEM
, the fatigue was explained by the downregulated throughput of pyruvate and consequently lower production of ATP with the residual enzymatic efficacy of the E
3
subunit or crossover of the E
2
as a proposed explanation of the fatigue severity. Functional diagnostics and visualization of instantaneous elevations of lactate and DHLA has been suggested. Novel treatment strategies have been implicated to compensate for chronic PDC impairment and hyperlactataemia. This hypothesis potentially influences the current understanding and treatment methods for any type of hyperlactataemia, fatigue, ME/
CFS
/SEID, and conditions associated with PDC impairment.
...
PMID:Suggested pathology of systemic exertion intolerance disease: Impairment of the E
3
subunit or crossover of swinging arms of the E
2
subunit of the pyruvate dehydrogenase complex decreases regeneration of cofactor dihydrolipoic acid of the E
2
subunit. 3138 26